Do analysts recommend ADXN or BPTH?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Addex Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Bio-Path 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is ADXN or BPTH more profitable?

Addex Therapeutics' return on equity of -105.98% beat Bio-Path's return on equity. Company Net Margins Return on Equity Return on Assets Addex Therapeutics N/A -105.98% -87.61% Bio-Path N/A -2,842.40% -337.48%

Do analysts rate CNSP or BPTH?

CNS Pharmaceuticals currently has a consensus target price of $20.00, suggesting a potential upside of 302.41%. Given CNS Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts plainly believe CNS Pharmaceuticals is more favorable than Bio-Path. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CNS Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Bio-Path 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable earnings & valuation, CNSP or BPTH?

CNS Pharmaceuticals is trading at a lower price-to-earnings ratio than Bio-Path, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CNS Pharmaceuticals N/A N/A -$15.85M -$29.63 N/A Bio-Path N/A N/A -$16.08M -$1.09 N/A

Is CNSP or BPTH more profitable?

CNS Pharmaceuticals' return on equity of -238.68% beat Bio-Path's return on equity. Company Net Margins Return on Equity Return on Assets CNS Pharmaceuticals N/A -238.68% -166.30% Bio-Path N/A -2,842.40% -337.48%

Do analysts recommend XBIO or BPTH?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Xenetic Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Bio-Path 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is XBIO or BPTH more profitable?

Bio-Path has a net margin of 0.00% compared to Xenetic Biosciences' net margin of -70.03%. Xenetic Biosciences' return on equity of -39.28% beat Bio-Path's return on equity. Company Net Margins Return on Equity Return on Assets Xenetic Biosciences -70.03% -39.28% -33.47% Bio-Path N/A -2,842.40% -337.48%

Do analysts rate BPTH or TNFA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bio-Path 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 TNF Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings & valuation, BPTH or TNFA?

Bio-Path is trading at a lower price-to-earnings ratio than TNF Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bio-Path N/A N/A -$16.08M -$1.09 N/A TNF Pharmaceuticals N/A N/A -$23.36M -$231.00 N/A

Is BPTH or TNFA more profitable?

TNF Pharmaceuticals' return on equity of -69.21% beat Bio-Path's return on equity. Company Net Margins Return on Equity Return on Assets Bio-Path N/A -2,842.40% -337.48% TNF Pharmaceuticals N/A -69.21% -33.98%

Do analysts prefer ACXP or BPTH?

Acurx Pharmaceuticals presently has a consensus target price of $31.00, indicating a potential upside of 1,790.24%. Given Acurx Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts clearly believe Acurx Pharmaceuticals is more favorable than Bio-Path. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Acurx Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Bio-Path 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher earnings & valuation, ACXP or BPTH?

Acurx Pharmaceuticals is trading at a lower price-to-earnings ratio than Bio-Path, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Acurx Pharmaceuticals N/A N/A -$7.97M -$4.05 N/A Bio-Path N/A N/A -$16.08M -$1.09 N/A

Is ACXP or BPTH more profitable?

Acurx Pharmaceuticals' return on equity of -153.92% beat Bio-Path's return on equity. Company Net Margins Return on Equity Return on Assets Acurx Pharmaceuticals N/A -153.92% -101.69% Bio-Path N/A -2,842.40% -337.48%

Bio-Path (BPTH) Competitors

$0.04 0.00 (0.00%)

As of 06/12/2026 02:44 PM Eastern

Compare

BPTH vs. ADXN, CNSP, XBIO, TNFA, and ACXP

Should you buy Bio-Path stock or one of its competitors? MarketBeat compares Bio-Path with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Bio-Path include Addex Therapeutics (ADXN), CNS Pharmaceuticals (CNSP), Xenetic Biosciences (XBIO), TNF Pharmaceuticals (TNFA), and Acurx Pharmaceuticals (ACXP). These companies are all part of the "pharmaceutical products" industry.

How does Bio-Path compare to Addex Therapeutics?

Addex Therapeutics (NASDAQ:ADXN) and Bio-Path (NASDAQ:BPTH) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, media sentiment, valuation, risk, institutional ownership, profitability, analyst recommendations and dividends.

In the previous week, Addex Therapeutics had 3 more articles in the media than Bio-Path. MarketBeat recorded 3 mentions for Addex Therapeutics and 0 mentions for Bio-Path. Addex Therapeutics' average media sentiment score of 0.61 beat Bio-Path's score of 0.00 indicating that Addex Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Addex Therapeutics	Positive
Bio-Path	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Addex Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Bio-Path	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Addex Therapeutics has a beta of 1.49, suggesting that its share price is 49% more volatile than the broader market. Comparatively, Bio-Path has a beta of -0.39, suggesting that its share price is 139% less volatile than the broader market.

16.1% of Addex Therapeutics shares are owned by institutional investors. Comparatively, 5.7% of Bio-Path shares are owned by institutional investors. 15.0% of Addex Therapeutics shares are owned by insiders. Comparatively, 0.7% of Bio-Path shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Addex Therapeutics has higher revenue and earnings than Bio-Path. Addex Therapeutics is trading at a lower price-to-earnings ratio than Bio-Path, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Addex Therapeutics	$210K	37.40	-$8.12M	-$5.74	N/A
Bio-Path	N/A	N/A	-$16.08M	-$1.09	N/A

Addex Therapeutics' return on equity of -105.98% beat Bio-Path's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Addex Therapeutics	N/A	-105.98%	-87.61%
Bio-Path	N/A	-2,842.40%	-337.48%

Summary

Addex Therapeutics beats Bio-Path on 10 of the 12 factors compared between the two stocks.

How does Bio-Path compare to CNS Pharmaceuticals?

CNS Pharmaceuticals (NASDAQ:CNSP) and Bio-Path (NASDAQ:BPTH) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, earnings, media sentiment, valuation and risk.

CNS Pharmaceuticals currently has a consensus target price of $20.00, suggesting a potential upside of 302.41%. Given CNS Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts plainly believe CNS Pharmaceuticals is more favorable than Bio-Path.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CNS Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Bio-Path	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

14.0% of CNS Pharmaceuticals shares are owned by institutional investors. Comparatively, 5.7% of Bio-Path shares are owned by institutional investors. 0.0% of CNS Pharmaceuticals shares are owned by insiders. Comparatively, 0.7% of Bio-Path shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

CNS Pharmaceuticals has a beta of 3.05, meaning that its share price is 205% more volatile than the broader market. Comparatively, Bio-Path has a beta of -0.39, meaning that its share price is 139% less volatile than the broader market.

In the previous week, CNS Pharmaceuticals had 3 more articles in the media than Bio-Path. MarketBeat recorded 3 mentions for CNS Pharmaceuticals and 0 mentions for Bio-Path. CNS Pharmaceuticals' average media sentiment score of 0.41 beat Bio-Path's score of 0.00 indicating that CNS Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
CNS Pharmaceuticals	Neutral
Bio-Path	Neutral

CNS Pharmaceuticals is trading at a lower price-to-earnings ratio than Bio-Path, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CNS Pharmaceuticals	N/A	N/A	-$15.85M	-$29.63	N/A
Bio-Path	N/A	N/A	-$16.08M	-$1.09	N/A

CNS Pharmaceuticals' return on equity of -238.68% beat Bio-Path's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CNS Pharmaceuticals	N/A	-238.68%	-166.30%
Bio-Path	N/A	-2,842.40%	-337.48%

Summary

CNS Pharmaceuticals beats Bio-Path on 10 of the 13 factors compared between the two stocks.

How does Bio-Path compare to Xenetic Biosciences?

Xenetic Biosciences (NASDAQ:XBIO) and Bio-Path (NASDAQ:BPTH) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, earnings, profitability, analyst recommendations, risk, media sentiment, institutional ownership and valuation.

15.1% of Xenetic Biosciences shares are held by institutional investors. Comparatively, 5.7% of Bio-Path shares are held by institutional investors. 7.6% of Xenetic Biosciences shares are held by insiders. Comparatively, 0.7% of Bio-Path shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xenetic Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Bio-Path	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Bio-Path has a net margin of 0.00% compared to Xenetic Biosciences' net margin of -70.03%. Xenetic Biosciences' return on equity of -39.28% beat Bio-Path's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xenetic Biosciences	-70.03%	-39.28%	-33.47%
Bio-Path	N/A	-2,842.40%	-337.48%

Xenetic Biosciences has higher revenue and earnings than Bio-Path. Xenetic Biosciences is trading at a lower price-to-earnings ratio than Bio-Path, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xenetic Biosciences	$2.98M	2.51	-$2.68M	-$1.20	N/A
Bio-Path	N/A	N/A	-$16.08M	-$1.09	N/A

In the previous week, Xenetic Biosciences had 2 more articles in the media than Bio-Path. MarketBeat recorded 2 mentions for Xenetic Biosciences and 0 mentions for Bio-Path. Xenetic Biosciences' average media sentiment score of 0.44 beat Bio-Path's score of 0.00 indicating that Xenetic Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Xenetic Biosciences	Neutral
Bio-Path	Neutral

Xenetic Biosciences has a beta of 2.19, indicating that its share price is 119% more volatile than the broader market. Comparatively, Bio-Path has a beta of -0.39, indicating that its share price is 139% less volatile than the broader market.

Summary

Xenetic Biosciences beats Bio-Path on 10 of the 13 factors compared between the two stocks.

How does Bio-Path compare to TNF Pharmaceuticals?

Bio-Path (NASDAQ:BPTH) and TNF Pharmaceuticals (NASDAQ:TNFA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, analyst recommendations, earnings, profitability, media sentiment, institutional ownership and valuation.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bio-Path	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
TNF Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

5.7% of Bio-Path shares are owned by institutional investors. Comparatively, 9.6% of TNF Pharmaceuticals shares are owned by institutional investors. 0.7% of Bio-Path shares are owned by company insiders. Comparatively, 0.5% of TNF Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

TNF Pharmaceuticals' return on equity of -69.21% beat Bio-Path's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bio-Path	N/A	-2,842.40%	-337.48%
TNF Pharmaceuticals	N/A	-69.21%	-33.98%

Bio-Path has a beta of -0.39, suggesting that its stock price is 139% less volatile than the broader market. Comparatively, TNF Pharmaceuticals has a beta of 2.04, suggesting that its stock price is 104% more volatile than the broader market.

In the previous week, TNF Pharmaceuticals had 1 more articles in the media than Bio-Path. MarketBeat recorded 1 mentions for TNF Pharmaceuticals and 0 mentions for Bio-Path. Bio-Path's average media sentiment score of 0.00 equaled TNF Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Bio-Path	Neutral
TNF Pharmaceuticals	Neutral

Bio-Path is trading at a lower price-to-earnings ratio than TNF Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bio-Path	N/A	N/A	-$16.08M	-$1.09	N/A
TNF Pharmaceuticals	N/A	N/A	-$23.36M	-$231.00	N/A

Summary

TNF Pharmaceuticals beats Bio-Path on 7 of the 10 factors compared between the two stocks.

How does Bio-Path compare to Acurx Pharmaceuticals?

Acurx Pharmaceuticals (NASDAQ:ACXP) and Bio-Path (NASDAQ:BPTH) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, risk, valuation, analyst recommendations, media sentiment and institutional ownership.

Acurx Pharmaceuticals' return on equity of -153.92% beat Bio-Path's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Acurx Pharmaceuticals	N/A	-153.92%	-101.69%
Bio-Path	N/A	-2,842.40%	-337.48%

Acurx Pharmaceuticals presently has a consensus target price of $31.00, indicating a potential upside of 1,790.24%. Given Acurx Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts clearly believe Acurx Pharmaceuticals is more favorable than Bio-Path.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acurx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Bio-Path	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Acurx Pharmaceuticals had 4 more articles in the media than Bio-Path. MarketBeat recorded 4 mentions for Acurx Pharmaceuticals and 0 mentions for Bio-Path. Acurx Pharmaceuticals' average media sentiment score of 0.97 beat Bio-Path's score of 0.00 indicating that Acurx Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Acurx Pharmaceuticals	Positive
Bio-Path	Neutral

Acurx Pharmaceuticals is trading at a lower price-to-earnings ratio than Bio-Path, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acurx Pharmaceuticals	N/A	N/A	-$7.97M	-$4.05	N/A
Bio-Path	N/A	N/A	-$16.08M	-$1.09	N/A

Acurx Pharmaceuticals has a beta of -2.09, indicating that its stock price is 309% less volatile than the broader market. Comparatively, Bio-Path has a beta of -0.39, indicating that its stock price is 139% less volatile than the broader market.

11.5% of Acurx Pharmaceuticals shares are held by institutional investors. Comparatively, 5.7% of Bio-Path shares are held by institutional investors. 20.3% of Acurx Pharmaceuticals shares are held by insiders. Comparatively, 0.7% of Bio-Path shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Acurx Pharmaceuticals beats Bio-Path on 10 of the 13 factors compared between the two stocks.

Get Bio-Path News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BPTH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BPTH vs. The Competition

Export

Metric	Bio-Path	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.91M	$970.92M	$6.50B	$12.37B
Dividend Yield	N/A	4.84%	2.67%	5.66%
P/E Ratio	-0.03	1.47	24.01	24.71
Price / Sales	N/A	127.72	540.55	165.59
Price / Cash	N/A	20.06	27.48	37.92
Price / Book	0.05	8.02	10.55	6.85
Net Income	-$16.08M	-$4.88M	$3.56B	$337.45M
7 Day Performance	N/A	4.75%	1.54%	2.70%
1 Month Performance	N/A	4.52%	2.48%	4.60%
1 Year Performance	N/A	47.58%	26.49%	32.81%

Bio-Path Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BPTH Bio-Path	N/A	$0.04 flat	N/A	-79.7%	$1.91M	N/A	N/A	10	Gap Down High Trading Volume
ADXN Addex Therapeutics	0.515 of 5 stars	$6.79 +15.9%	N/A	-21.8%	$7.22M	$210K	N/A	30	Gap Up
CNSP CNS Pharmaceuticals	3.0072 of 5 stars	$4.59 -6.1%	$20.00 +335.7%	-49.5%	$7.15M	N/A	N/A	5	Short Interest Increase
XBIO Xenetic Biosciences	0.601 of 5 stars	$3.08 -0.3%	N/A	+2.9%	$7.08M	$2.98M	N/A	4	Short Interest Increase
TNFA TNF Pharmaceuticals	0.0227 of 5 stars	$3.78 +1.9%	N/A	-71.8%	$6.98M	N/A	N/A	6

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BPTH) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bio-Path (BPTH) Competitors

BPTH vs. ADXN, CNSP, XBIO, TNFA, and ACXP

How does Bio-Path compare to Addex Therapeutics?

Summary

How does Bio-Path compare to CNS Pharmaceuticals?

Summary

How does Bio-Path compare to Xenetic Biosciences?

Summary

How does Bio-Path compare to TNF Pharmaceuticals?

Summary

How does Bio-Path compare to Acurx Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BPTH vs. The Competition

Bio-Path Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Bio-Path (BPTH) Competitors

BPTH vs. ADXN, CNSP, XBIO, TNFA, and ACXP

How does Bio-Path compare to Addex Therapeutics?

Does the media refer more to ADXN or BPTH?

Do analysts recommend ADXN or BPTH?

Which has more risk & volatility, ADXN or BPTH?

Do insiders & institutionals believe in ADXN or BPTH?

Which has better earnings and valuation, ADXN or BPTH?

Is ADXN or BPTH more profitable?

Summary

How does Bio-Path compare to CNS Pharmaceuticals?

Do analysts rate CNSP or BPTH?

Do insiders & institutionals hold more shares of CNSP or BPTH?

Which has more risk and volatility, CNSP or BPTH?

Does the media refer more to CNSP or BPTH?

Which has preferable earnings & valuation, CNSP or BPTH?

Is CNSP or BPTH more profitable?

Summary

How does Bio-Path compare to Xenetic Biosciences?

Do insiders and institutionals believe in XBIO or BPTH?

Do analysts recommend XBIO or BPTH?

Is XBIO or BPTH more profitable?

Which has stronger valuation & earnings, XBIO or BPTH?

Does the media refer more to XBIO or BPTH?

Which has more risk and volatility, XBIO or BPTH?

Summary

How does Bio-Path compare to TNF Pharmaceuticals?

Do analysts rate BPTH or TNFA?

Do insiders & institutionals believe in BPTH or TNFA?

Is BPTH or TNFA more profitable?

Which has more risk and volatility, BPTH or TNFA?

Does the media favor BPTH or TNFA?

Which has stronger earnings & valuation, BPTH or TNFA?

Summary

How does Bio-Path compare to Acurx Pharmaceuticals?

Is ACXP or BPTH more profitable?

Do analysts prefer ACXP or BPTH?

Does the media refer more to ACXP or BPTH?

Which has higher earnings & valuation, ACXP or BPTH?

Which has more volatility & risk, ACXP or BPTH?

Do institutionals and insiders believe in ACXP or BPTH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BPTH vs. The Competition

Bio-Path Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools